M 177 (Divalproex sodium extended-release 250 mg)
Pill imprint M 177 has been identified as Divalproex sodium extended-release 250 mg.
Divalproex sodium is used in the treatment of bipolar disorder; migraine prevention; epilepsy; mania; hyperekplexia (and more), and belongs to the drug class fatty acid derivative anticonvulsants. There is positive evidence of human fetal risk during pregnancy. Divalproex sodium 250 mg is not subject to the Controlled Substances Act.
See also related documents.
Images for M 177 (Divalproex sodium extended-release 250 mg)
- 250 mg
- 12.00 mm
- Prescription only
- Drug Class:
- Fatty acid derivative anticonvulsants
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- N - Not a controlled drug
- Mylan Pharmaceuticals Inc.
- National Drug Code (NDC):
- Inactive Ingredients:
|NDC Code||Manufacturer / Repackager|
|51079-0766||UDL Laboratories Inc|
Note: Inactive ingredients may vary.
Divalproex sodium extended-release is associated with the treatment of:
Search by Imprint, Shape or Color
Note: All fields are optional. Use the pill finder to identify medications by visual appearance or name. All Rx and OTC drugs in the US are required by the FDA to have an imprint. If your pill has no imprint it could be a vitamin, diet/herbal/energy pill, illicit or foreign drug. More about imprint codes...